Skip to main content

Table 2 Results obtained by using BEV in MGs

From: Retrospective analysis to evaluate the efficacy and the safety of Bevacizumab in the treatment of recurrent malignant gliomas

 

n (%)

Objective responses

 Complete response (CR)

1 (5.9)

 Partial response (PR)

7 (41.2)

 Stable disease (SD)

3 (17.6)

 Progressive disease (PD)

6 (35.3)

 Overall response rate (ORR)

8 (47.1)

 Disease control (DC)

11 (64.7)

Survival data

 6 months-PFS, %

41.2

 12 months-PFS, %

29.4

 Median PFS, months (range)

5 (1-40)

 6 months-OS, %

58.8

 12 months-OS, %

35.3

 Median OS, months (range)

8.3 (1-45)

  1. PFS progression free survival, OS overall survival